MDA (Medical Devices Agency) reassures industry on fees in MCA (Medicines Control Agency) merger
This article was originally published in Clinica
UK medical device manufacturers will not be subject to the fees that currently apply to their pharmaceutical counterparts when the two industries' regulatory bodies merge in April 2003 (see Clinica No 1012, pp 3-4). This reassurance was made by David Jefferys, chief executive of the (MDA), at the 10th annual conference on device regulation, hosted by the Association of British Health-Care Industries.
You may also be interested in...
Australia’s competition regulator, the ACCC, has granted a conditional dispensation to allow generics industry association the GBMA and brand body Medicines Australia to work together to help address the coronavirus pandemic by sharing information on stock, inventory, manufacturing and the supply chain. However, tender pricing will not be among the subjects discussed.
The UK biotech's CEO tells Scrip that Izana's objective is to treat rapidly deteriorating COVID-19 patients before ICU admission and prior to ventilation.
Exclusive: HBW Insight speaks to HRA Pharma CEO David Wright about the company's plans to become a top-10 global OTC player. Wright reveals that HRA is about to enter Latin America, beginning with Mexico and Brazil, and is currently looking at at least two significant acquisitions to ramp up its expansion plans in the coming months.